Is boiled food spice curcumin still biologically active? An experimental exploration

  • Liang Shen
  • Hui-Hui Jiang
  • Hong-Fang Ji
Keywords: curcumin, degradation, oxidative damage, apoptosis, PC12 cells


Background: As the major active component of turmeric (Curcuma longa), curcumin is widely used as a spice and food coloring agent, and also possesses multiple biological activities and therapeutic potential for neurodegenerative diseases. To answer the paradox between curcumin’s biological activities and poor systemic bioavailability, we proposed that degradation products of curcumin may make important contributions to its biological activities, which needs to be verified. In addition, curcumin is usually heated or boiled used as a spice, it is necessary to explore whether boiled curcumin, which degrades readily, is still biologically active.

Methods: Thus, in the present study we investigated the protective effects of curcumin and boiled curcumin mixture on H2O2-induced oxidative damage in PC12 cells, a widely used model for neurons.

Results: Results showed that in spite of high degradation rates, boiled curcumin mixture still possessed similar protective activities like parent curcumin, and could effectively rescue PC12 cells against H2O2-induced damage, via decreasing production of reactive oxygen species and malondialdehyde, reducing caspase-3 and caspase-9 activities. Moreover, curcumin’s degradation products including ferulic acid, vanillin and vanillic acid could also improve PC12 cells survival rate.

Conclusion: Our findings indicated that boiled curcumin mixtures still possessed protective activity for PC12 cells, and supported the contribution of degradation products to biological activities of curcumin.


Download data is not yet available.


  1. Singh S. From exotic spice to modern drug? Cell 2007; 130: 765–8.

  2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. CurcumIn: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1–75.

  3. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30: 85–94.

  4. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76: 1590–611.

  5. Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev 2013; 66: 222–307.

  6. Aggarwal BB, Yuan W, Li S, Gupta SC. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: identification of novel components of turmeric. Mol Nutr Food Res 2013; 57: 1529–42.

  7. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumIn: preclinical and clinical studies. Anticancer Res 2003; 23: 363–98.

  8. Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res 2015; 35: 645–51.

  9. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumIn: how spicy is it? Mol Nutr Food Res 2008; 52: 1010–30.

  10. Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease. Br J Nutr 2016; 115: 449–65.

  11. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs 2012; 21: 1123–40.

  12. Ji HF, Shen L. The multiple pharmaceutical potential of curcumin in Parkinson's disease. CNS Neurol Disord Drug Targets 2014; 13: 369–73.

  13. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892–901.

  14. Shen L, Ji HF. The pharmacology of curcumIn: is it the degradation products? Trends Mol Med 2012; 18: 138–44.

  15. Shen L, Ji HF. Contribution of degradation products to the anticancer activity of curcumin. Clin Cancer Res 2009; 15: 7108–9.

  16. Ji HF, Shen L. Can improving bioavailability improve the bioactivity of curcumin? Trends Pharmacol Sci 2014; 35: 265–6.

  17. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867–76.

  18. Lin JK, Pan MH, Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000; 13: 153–8.

  19. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumIn: problems and promises. Mol Pharm 2007; 4: 807–18.

  20. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491–9.

  21. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894–900.

  22. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.

  23. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol 2008; 75: 787–809.

  24. Siddiqui MA, Kashyap MP, Kumar V, Tripathi VK, Khanna VK, Yadav S, et al. Differential protection of pre-, co- and post-treatment of curcumin against hydrogen peroxide in PC12 cells. Hum Exp Toxicol 2011; 30: 192–8.

  25. Park SY, Kim HS, Cho EK, Kwon BY, Phark S, Hwang KW, et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol 2008; 46: 2881–7.

  26. Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr 2007; 40: 92–100.

  27. Shen L, Ji HF. Theoretical study on physicochemical properties of curcumin. Spectrochimic Acta A Mol Biomol Spectrosc 2007; 67: 619–23.

  28. Makni M, Chtourou Y, Fetoui H, Garoui el M, Boudawara T, Zeghal N. Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. Eur J Pharmacol 2011; 668: 133–9.

  29. Shen Y, Zhang H, Wang L, Qian H, Qi Y, Miao X, et al. Protective effect of ferulic acid against 2,2'-azobis(2-amidinopropane) dihydrochloride-induced oxidative stress in PC12 cells. Cell Mol Biol 2016; 62: 109–16.

  30. Yao SW, Wen XX, Huang RQ, He RR, Ou SY, Shen WZ, et al. Protection of feruloylated oligosaccharides from corn bran against oxidative stress in PC 12 cells. J Agric Food Chem 2014; 62: 668–74.

  31. Kim HJ, Hwang IK, Won MH. Vanillin, 4-hydroxybenzyl aldehyde and 4-hydroxybenzyl alcohol prevent hippocampal CA1 cell death following global ischemia. Brain Res 2007; 1181: 130–41.

  32. Shen L, Liu CC, An CY, Ji HF. How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Sci Rep 2016; 6: 20872.

  33. Wang G, Gong Y, Burczynski FJ, Hasinoff BB. Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay. Free Radic Res 2008; 42: 435–41.

How to Cite
Shen L., Jiang H.-H., & Ji H.-F. (2018). Is boiled food spice curcumin still biologically active? An experimental exploration. Food & Nutrition Research, 62.
Original Articles